Loading...
•
Dec 31, 2022
OptimizeRx Q4 2022 Earnings Report
Reported results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
OptimizeRx reported its Q4 and full year 2022 financial results, highlighting the challenges faced due to macro headwinds and the strategic shift towards advanced solutions like RWD-AI. Despite a conservative outlook for 2023, the company sees positive momentum with several RWD-AI deals and anticipates a return to double-digit revenue growth.
OptimizeRx faced challenges due to macro headwinds in 2022.
The company strengthened its platform and team around advanced solutions, particularly RWD-AI.
OptimizeRx exited 2022 with six RWD-AI deals and a growing RWD-AI pipeline.
The company anticipates a return to at least double digit revenue growth in 2023.
OptimizeRx
OptimizeRx
Forward Guidance
For the full year 2023, OptimizeRx expects net revenues to increase at least 10% year-over-year, and gross margins to be between 58% and 62%. OptimizeRx is providing revenue guidance for its fiscal first quarter ending March 31, 2023 and is looking for revenue to come in between $11.5 million and $13 million.
Positive Outlook
- Net revenues are expected to increase at least 10% year-over-year in 2023.
- Gross margins are expected to be between 58% and 62% in 2023.
- Revenue guidance for Q1 2023 is between $11.5 million and $13 million.
- The company anticipates a return to at least double digit revenue growth in 2023.